Merck & Co. Stock - long-term cancer franchise and pipeline in focus

Merck & Co. leans on its blockbuster cancer drug Keytruda and a broad late-stage pipeline to shape its long-term growth story. This Saturday deep dive looks at the company’s business model, core products and strategic priorities beyond the latest quarter.

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 18:38 CET. Details in the imprint.

Merck & Co. (US58933Y1055) relies heavily on blockbuster cancer drug Keytruda and a broad late-stage pipeline for its growth narrative. With no fresh market-moving headlines today, this Saturday review focuses on the group’s long-term strategy and business model.

Keytruda as the growth engine

Merck’s revenue mix is dominated by oncology, in particular immune checkpoint inhibitor Keytruda, which has become one of the world’s top-selling prescription medicines. Keytruda generated tens of billions of dollars in annual sales recently, underpinning Merck’s cash flow and R&D budget.

The drug is approved across a wide range of cancers, including lung, melanoma, kidney and head and neck tumors, often in combination regimens. Regulators in the United States, Europe and other regions continue to expand the label as additional trial data read out over time.

Broad late-stage pipeline and diversification

Beyond Keytruda, Merck has built a sizable late-stage pipeline in oncology, vaccines and cardiometabolic disease. The company highlights programs in areas such as prostate cancer, renal cell carcinoma and hematologic malignancies, alongside next-generation vaccines.

Merck also runs a meaningful animal health business, which provides vaccines and treatments for livestock and companion animals. This unit adds a more stable, less patent-sensitive revenue stream, helping smooth earnings across the pharmaceutical cycle.

How Merck earns its money

Merck & Co. generates most of its revenue from patented prescription drugs and vaccines sold to hospitals, physicians, pharmacies and government purchasers around the world. The company invests heavily in research and development to discover and advance new therapies.

Royalties, alliances and co-promotion agreements supplement product sales, including collaborations with other large pharmaceutical companies on specific drugs. The animal health division contributes additional sales and operating profit, broadening the business base.

Capital allocation and shareholder returns

Merck pursues a balanced capital allocation strategy that prioritizes R&D investment, targeted acquisitions and shareholder returns via dividends and buybacks. The group has a long track record of paying a regular quarterly dividend to its shareholders.

According to stock-market data providers, Merck’s dividend yield recently stood close to 3%, positioning the stock as a combined growth and income name within the large-cap pharma space. Management typically reviews the payout annually, subject to board approval.

Positioning within global pharma

Merck ranks among the largest global pharmaceutical companies by market capitalization, with a recent value in the high hundreds of billions of dollars. The stock trades on the New York Stock Exchange under the ticker MRK.

Within the medical sector, Merck is categorized in the pharmaceuticals and large-cap pharma industry group. It is a member of major US equity benchmarks, including the Standard & Poor’s 500 index, which helps anchor its shareholder base among global institutional investors.

Key long-term opportunities and risks

On the opportunity side, Merck’s long-term story is tied to extending Keytruda’s lifecycle, launching follow-on oncology assets and expanding in vaccines and cardiometabolic disease. Successful late-stage trials can translate into new indications or entirely new products.

However, investors also track patent expiry timelines, especially for Keytruda in the early 2030s, and the potential impact of biosimilar competition thereafter. Pricing pressures, regulatory changes and outcomes-based reimbursement models represent additional structural risks.

The product behind the stock

One of Merck’s flagship products is the cancer immunotherapy Keytruda (pembrolizumab), a monoclonal antibody that helps the immune system recognize and attack tumor cells. It is used alone or with other treatments in multiple advanced cancer indications worldwide.

Where the stock trades today

Merck & Co. shares (US58933Y1055) trade on the New York Stock Exchange at around $114 per share as of 06/18/2026, 16:00 ET, according to recent quote data from major financial portals.

Key facts on Merck & Co. stock

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• WKN: A3ES87
• Ticker: MRK
• Venue: NYSE
• Price (as of 06/18/2026, 16:00 ET): 114.04 USD
• Market cap: 281.65 billion USD (as of 06/18/2026)
• Sector / Industry: Health Care / Pharmaceuticals, Large Cap Pharma
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.